Ritu Salani, MD

Ritu Salani, MD

Gynecologic Oncology
Primary Location
Westwood OBGYN
200 Medical Plaza
Los Angeles, California 90095


Medical Board Certifications

Obstetrics and Gynecology, American Board of Obstetrics and Gynecology, 2019
Gynecologic Oncology, American Board of Obstetrics and Gynecology, 2012


Johns Hopkins University School of Medicine-GME, 2008


Emory University School of Medicine, 2005


The Johns Hopkins University School of Medicine., MBA, 2008
Northeast Ohio Medical University, MD, 2001


West Los Angeles

Westwood OBGYN

Obstetrics and Gynecology| Women's Health| Cancer Genetics +2 more

Hospital Affiliations

Ronald Reagan UCLA Medical Center

UCLA Santa Monica Medical Center

Areas of Focus

Minimally invasive gynecologic surgery
Ovarian cancer
Ovarian debulking surgery
Endometrial cancer
Cervical cancer
Cancer chemotherapy



  1. Barnes DR, Rookus MA, McGuffog L…Salani R…Antoniou AC. Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA 1 and BRCA 2 pathogenic variants. Genet Med 2020, accepted for publication. PMID 32665703
  2. Harkenrider MM, Markham MJ, Dizon DS, Jhingran A, Salani R, Serour RK, Lynn J, Kohn EC. Moving forward in cervical cancer-enhancing susceptibility to DNA repair inhibition and damage: NCI Clinical Trials Planning Meeting Report. J Natl Cancer Inst 2020; accepted for publication. PMID 32219419
  3. Teoh D, Musa F, Salani R, Huh W, Jimenez E. Diagnosis and management of adenocarcinoma in situ: A Society of Gynecologic Oncology evidence-based review and recommendations. Obstet Gynecol 2020;135(4):869-78. PMID 32168211
  4. Chase D, Huang HQ, Monk BJ…Salani R…Tewari KS. Patient-reported outcomes at discontinuation of anti-angiogenesis therapy in the randomized trial of chemotherapy with bevacizumab for advanced cervical cancer: an NRG Oncology Group study. Int J Gynecol Cancer 2020;30(5):596-601. PMID 32114513
  5. Hutchcraft ML, Smith B, McLaughlin EM, Hade EM, Backes FJ, O'Malley DM, Cohn DE, Fowler JM, Copeland LJ, Salani R. Conization pathologic features as a predictor of intermediate and high risk features on radical hysterectomy specimens in early stage cervical cancer. Gynecol Oncol 2019; 153(2):255-8. PMID 30718123
  6. Rose PG, Java JJ, Salani R…Copeland LJ. Nomogram for Predicting Individual Survival After Recurrence of Advanced-Stage, High-Grade Ovarian Carcinoma. Obstet Gynecol 2019;133;(2):245-254. PMID 30633128
  7. Randall ME, Filiaci V, McMeekin DS…Salani R…Miller DS. Phase III trial of adjuvant pelvic radiation therapy versus vaginal cuff brachytherapy plus paclitaxel/carboplatin chemotherapy in high-intermediate and high risk, early stage endometrial cancer. J Clin Oncol 2019;37(21):1810-18. PMID 30995174
  8. von Gruenigen VE, Huang HQ, Cella D, Zevon M, LaChance JA, Waker JL, Salani R, Modesitt SC, Morris RT, Bradley WH, Boente MP, Wenzel L. Quality of life, symptoms and care needs in patients with persistent or recurrent platinum-resistant ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2018;150(1):119-26. PMID 29778506
  9. Salani R, Khanna N, Frimer M, Bristow RE, Chen LM. An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 2017;146(1):3-10. PMID 28372871
  10. Thaker PH*, Salani R*, Brady WE, Lankes HA, Cohn DE, Mutch DG, Mannel RS, Bell-McGuinn KM, DiSilvestro PA, Jelovac D, Carter JS, Duan W, Resnick KE, Dizon DS, Aghajanian C, Fracasso PM. A phase I trial of paclitaxel, cisplatin and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852). Ann Oncol 2016;28(3):505-511. PMID 27998970 *Both authors contributed equally for first authorship.

Link to Dr. Salani's PubMed publications


  • Best Doctors in America, 2012-2020
  • GOG Scholar Investigator Award, 2019
  • APGO Excellence in Teaching Award, 2015